NeuroOne Announces Reverse Stock Split to Regain Nasdaq Compliance

Got story updates? Submit your updates here. ›

NeuroOne Medical Technologies Corporation, a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, announced it will effect a 1-for-6 reverse stock split of its common stock. The reverse split is part of the company's plan to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Why it matters

NeuroOne's reverse split is a common tactic for companies seeking to boost their stock price and avoid delisting from a major exchange like Nasdaq. Maintaining a minimum share price is crucial for medical device firms like NeuroOne to attract investors and access capital markets.

The details

The reverse stock split will become effective at 5:00 p.m. Eastern Time on April 15, 2026, with the company's common stock expected to begin trading on a split-adjusted basis the next day. Fractional shares will not be issued, and stockholders entitled to a fractional share will receive a cash payment instead. Proportionate adjustments will also be made to NeuroOne's outstanding stock options and equity incentive plans.

• The reverse stock split will become effective at 5:00 p.m. Eastern Time on April 15, 2026.
• NeuroOne's common stock is expected to begin trading on a split-adjusted basis on April 16, 2026.

What’s next

The reverse stock split was approved by NeuroOne's stockholders at its 2026 annual meeting on April 3, 2026. The company's Board of Directors subsequently approved the 1-for-6 reverse split ratio.